Jamie Williams
Family · Lynchburg, VANPI 1376113050
Payments from drug & device makers
Across 120 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$475
- GSK$388
- Sanofi$277
- Amgen$220
- Harmony Biosciences LLC$129
- Takeda Pharmaceuticals U.S.A., Inc.$107
- plus $691 from 15 others
What the payments were for
- Food & beverage$2,23198%
- Education$552%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $475 |
| GSK | 29 | $388 |
| Sanofi | 11 | $277 |
| Amgen | 11 | $220 |
| Harmony Biosciences LLC | 4 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $107 |
| Pfizer | 6 | $102 |
| United Therapeutics Corporation | 4 | $95 |
| Merck | 3 | $91 |
| Novartis | 3 | $72 |
| Regeneron Healthcare Solutions, Inc. | 2 | $57 |
| Boehringer Ingelheim | 2 | $50 |
| Grifols USA, LLC | 2 | $45 |
| Mallinckrodt Hospital Products Inc. | 1 | $37 |
| Actelion Pharmaceuticals US, Inc. | 1 | $33 |
| Electromed, Inc. | 1 | $28 |
| Baxter Healthcare | 1 | $21 |
| Philips North America LLC | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
How this compares
$2,286 in reported general payments places this provider in the 80th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 237 | $248,014 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 82 | $46,809 |
| Spiriva RespimatTiotropium Bromide | 43 | $46,397 |
| Breo ElliptaFluticasone/Vilanterol | 68 | $41,450 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $29,982 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 32 | $29,162 |
| EliquisApixaban | 37 | $28,777 |
| Incruse ElliptaUmeclidinium Bromide | 22 | $17,144 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 53 | $10,197 |
| Arnuity ElliptaFluticasone Furoate | 27 | $8,411 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $7,846 |
| Spiriva HandihalerTiotropium Bromide | 13 | $7,412 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 192 | $6,651 |
| Tiotropium Bromide | 11 | $4,195 |
| Wixela InhubFluticasone Propion/Salmeterol | 24 | $3,638 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $388 | $361,828436 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $50 | $75,55975 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $475 | $37,82851 claims |
| PfizerEliquis | $102 | $28,77737 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,332 family providers in Virginia.
Other family in Lynchburg
- Amy StowersLynchburg$23K
- Elizabeth CopesLynchburg$23K
- Shauntell KlineLynchburg$15K
- Haley RussellLynchburg$13K
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.